Advertisement

Digestive Diseases and Sciences

, Volume 60, Issue 5, pp 1382–1388 | Cite as

Efficacy of Concomitant Elemental Diet Therapy in Scheduled Infliximab Therapy in Patients with Crohn’s Disease to Prevent Loss of Response

  • Noriko KamataEmail author
  • Nobuhide Oshitani
  • Kenji Watanabe
  • Kimihiko Watanabe
  • Shuhei Hosomi
  • Atsushi Noguchi
  • Tomomi Yukawa
  • Hirokazu Yamagami
  • Matsatsugu Shiba
  • Tetsuya Tanigawa
  • Toshio Watanabe
  • Kazunari Tominaga
  • Yasuhiro Fujiwara
  • Tetsuo Arakawa
Original Article

Abstract

Background

Loss of response (LOR) to infliximab (IFX) has become an important clinical issue for patients with Crohn’s disease (CD). Elemental diet (ED) therapy has been established as a nutrition therapy for CD in Japan. ED therapy can reduce antigen exposure and is both efficacious and safe.

Aim

To evaluate the efficacy of concomitant ED therapy in maintaining regular IFX infusion in patients with CD.

Methods

We retrospectively studied 125 patients with luminal CD treated with scheduled IFX maintenance therapy with a regular dosage. Patients were classified into two groups: the ED group with intake ≥900 kcal/day and the non-ED group with intake <900 kcal/day. When clinical LOR was detected on the basis of disease activity, laboratory parameters, or endoscopic findings, the physician discontinued the infusion schedule of IFX. We investigated the efficacy of ED therapy for sustaining the scheduled IFX maintenance therapy.

Results

With the exception of ED intake, no significant differences were found in patient characteristics between the ED group and the non-ED group. The ED group was significantly superior to the non-ED group (p = 0.049) in sustaining scheduled IFX maintenance therapy. It is well known that ED therapy is more effective for small bowel lesions than colonic lesions in CD. When comparing ileitis and ileocolitis patients with CD, the ED group was significantly superior to the non-ED group (p = 0.015).

Conclusions

Concomitant ED therapy is effective in maintaining scheduled IFX maintenance therapy in patients with luminal CD in order to prevent LOR.

Keywords

Crohn’s disease Infliximab Loss of response Elemental diet 

Notes

Conflict of interest

None.

References

  1. 1.
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337:1029–1035.CrossRefPubMedGoogle Scholar
  2. 2.
    Hanauer SB, Fegan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s diseasee: the ACCENT I randomized trial. Lancet. 2002;359:1541–1549.CrossRefPubMedGoogle Scholar
  3. 3.
    Bhatia JK, Korelitz BI, Panagopoulos G, et al. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn’s disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J Clin Gastroenterol. 2007;41:677–681.CrossRefPubMedGoogle Scholar
  4. 4.
    Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in CD. Inflamm Bowel Dis. 2009;15:1295–1301.CrossRefPubMedGoogle Scholar
  5. 5.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;15:1383–1395.CrossRefGoogle Scholar
  7. 7.
    Mackey AC, Green L, Leptak C. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386–388.CrossRefPubMedGoogle Scholar
  8. 8.
    Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24:1333–1400.CrossRefPubMedGoogle Scholar
  9. 9.
    Tanaka T, Takahama K, Kimura T, et al. Effect of concurrent elemental diet on infliximab treatment for Crohn’s disease. J Gastroenterol Hepatol. 2006;21:1143–1149.CrossRefPubMedGoogle Scholar
  10. 10.
    Hirai F, Ishihara H, Yada S, et al. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn’s disease in adults. Dig Dis Sci. 2013;58:1329–1334.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Satsangi J, Silverberg MS, Vermeire S. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Matsueda K, Shoda R, Takazoe M, et al. Therapeutic efficacy of cyclic home elemental enteral alimentation in Crohn’s disease: Japanese Cooperative Crohn’s Disease Study. J Gastroenterol. 1995;30:91–94.PubMedGoogle Scholar
  13. 13.
    Hirakawa H, Fukuda Y, Tanida N, et al. Home elemental enteral hyperalimentation (HEEH) for maintenance of remission in patients with Crohn’s disease. Gastroenterol Jpn. 1993;28:379–384.PubMedGoogle Scholar
  14. 14.
    Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease. Gut. 1996;38:543–548.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767.CrossRefPubMedGoogle Scholar
  16. 16.
    Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol.. 2006;4:1248–1254.CrossRefPubMedGoogle Scholar
  17. 17.
    Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40–47.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962–971.CrossRefPubMedGoogle Scholar
  19. 19.
    D’Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and hot to predict response? Am J Gastroenterol. 2011;106:199–212.CrossRefPubMedGoogle Scholar
  20. 20.
    Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn’s disease. Dig Liver Dis. 2000;32:769–774.CrossRefPubMedGoogle Scholar
  21. 21.
    Lochs H. Enteral nutrition—the new maintenance therapy in Crohn’s disease? Inflamm Bowel Dis. 2007;13:1581–1582.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Noriko Kamata
    • 1
    Email author
  • Nobuhide Oshitani
    • 2
  • Kenji Watanabe
    • 3
  • Kimihiko Watanabe
    • 1
  • Shuhei Hosomi
    • 1
  • Atsushi Noguchi
    • 1
  • Tomomi Yukawa
    • 1
  • Hirokazu Yamagami
    • 1
  • Matsatsugu Shiba
    • 1
  • Tetsuya Tanigawa
    • 1
  • Toshio Watanabe
    • 1
  • Kazunari Tominaga
    • 1
  • Yasuhiro Fujiwara
    • 1
  • Tetsuo Arakawa
    • 1
  1. 1.Department of GastroenterologyOsaka City University Graduate School of MedicineOsakaJapan
  2. 2.Department of Medicine, Social Welfare Service Corporation, Ishii Memorial Aizen-enAizeznbashi HospitalOsakaJapan
  3. 3.Department of GastroenterologyOsaka City General HospitalOsakaJapan

Personalised recommendations